{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:25:51Z","timestamp":1794561951146,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26K10833"],"award-info":[{"award-number":["26K10833"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ymgme.2026.110137","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:04:17Z","timestamp":1777647857000},"page":"110137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AAV9\/hGLA gene therapy reduces podocyte GL-3 accumulation in a Fabry disease mouse model"],"prefix":"10.1016","volume":"148","author":[{"given":"Takahiro","family":"Kanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Sehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanako","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ymgme.2026.110137_bb0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110137_bb0010","first-page":"39","article-title":"Foot process effacement with normal urinalysis in classic Fabry disease","volume":"1","author":"Kanai","year":"2011","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110137_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13023-024-03412-6","article-title":"Quality of life and unmet needs in patients with Fabry disease: a qualitative study","volume":"19","author":"Morales","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110137_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031887","article-title":"Chaperone therapy in Fabry disease","volume":"23","author":"Weidemann","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.ymgme.2026.110137_bb0025","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00391-17","article-title":"Adeno-associated virus (AAV) serotypes have distinctive interactions with domains of the cellular AAV receptor","volume":"91","author":"Pillay","year":"2017","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110137_bb0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymgme.2026.110137_bb0035","doi-asserted-by":"crossref","first-page":"7691","DOI":"10.2147\/IJN.S459905","article-title":"Adeno-associated virus engineering and load strategy for tropism modification, immune evasion and enhanced transgene expression","volume":"19","author":"Zhou","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.ymgme.2026.110137_bb0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase a and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110137_bb0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase a","volume":"15","author":"Ziegler","year":"2007","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.ymgme.2026.110137_bb0050","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110137_bb0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110137_bb0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.kint.2025.09.027","article-title":"Mouse Alport podocytes are susceptible to AAV9 transduction in vivo","volume":"109","author":"Lin","year":"2026","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.ymgme.2026.110137_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/genes16070766","article-title":"Comparative evaluation of AAV8 and AAV9 gene therapy in Fabry knockout (Gla(\u2212\/y)) and symptomatic (G3S(Tg\/+)Gla(\u2212\/y)) murine models","volume":"16","author":"Chang","year":"2025","journal-title":"Genes (Basel)"},{"issue":"5","key":"10.1016\/j.ymgme.2026.110137_bb0070","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1073\/pnas.051634498","article-title":"Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice","volume":"98","author":"Jung","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.ymgme.2026.110137_bb0075","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110137_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jb\/mvq125","article-title":"Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease","volume":"149","author":"Shiozuka","year":"2011","journal-title":"J. Biochem."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110137_bb0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"Taguchi","year":"2013","journal-title":"Biochem. J."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2026.110137_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1089\/hum.2021.106","article-title":"Higher transduction efficiency of AAV5 to neural stem cells and immature neurons in gerbil dentate gyrus compared to AAV2 and rh10","volume":"33","author":"Sehara","year":"2022","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"10.1016\/j.ymgme.2026.110137_bb0095","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.3390\/cimb46080499","article-title":"Therapeutic application and structural features of adeno-associated virus vector","volume":"46","author":"Matsuzaka","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"19","key":"10.1016\/j.ymgme.2026.110137_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00843-21","article-title":"Adeno-associated virus 9 structural rearrangements induced by endosomal trafficking pH and glycan attachment","volume":"95","author":"Penzes","year":"2021","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.ymgme.2026.110137_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262010226","article-title":"Deacidification of the Endolysosomal system by the vesicular proton pump V-ATPase inhibitor bafilomycin A1 affects EGF receptor endocytosis differently in endometrial MSC and HeLa cells","volume":"26","author":"Salova","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110137_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3560","article-title":"Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in \u03b1-galactosidase A-deficient mice","volume":"25","author":"Hayashi","year":"2023","journal-title":"J. Gene Med."},{"issue":"5\u20136","key":"10.1016\/j.ymgme.2026.110137_bb0115","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/hum.2023.106","article-title":"Therapeutic strategy for Fabry disease by intravenous Administration of Adeno-Associated Virus 9 in a symptomatic mouse model","volume":"35","author":"Hayashi","year":"2024","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110137_bb0120","doi-asserted-by":"crossref","first-page":"2459931","DOI":"10.1080\/1547691X.2025.2459931","article-title":"Generation of cynomolgus monkey capsid-specific positive control cells for IFN\u03b3 ELISpot assays for adeno-associated gene therapy applications","volume":"22","author":"Casinghino","year":"2025","journal-title":"J. Immunotoxicol."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110137_bb0125","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1128\/JVI.07232-11","article-title":"Structural insight into the unique properties of adeno-associated virus serotype 9","volume":"86","author":"DiMattia","year":"2012","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110137_bb0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2026.110137_bb0135","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.ymgme.2026.110137_bb0140","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2026.110137_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omtm.2023.01.003","article-title":"Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease","volume":"28","author":"Saleh","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110137_bb0150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/10915818251318248","article-title":"Mutagenesis and carcinogenesis risk evaluation for AAV and lentiviral gene therapies","volume":"44","author":"Parman","year":"2025","journal-title":"Int. J. Toxicol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226004208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226004208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:24:28Z","timestamp":1794558268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226004208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1096719226004208"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110137","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV9\/hGLA gene therapy reduces podocyte GL-3 accumulation in a Fabry disease mouse model","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110137"}}